Literature DB >> 1312760

Glucocorticoids decrease vitamin D receptor number and gene expression in human osteosarcoma cells.

M Godschalk1, J R Levy, R W Downs.   

Abstract

The mechanisms by which glucocorticoids (GC) inhibit some actions of vitamin D [1,25-(OH)2D3] are not well understood, but there is growing evidence that GC alter vitamin D receptor (VDR) number. We studied the effects of dexamethasone (DEX) on VDR number and mRNA in the human osteosarcoma cell line, MG-63. The effects of DEX on 1,25-(OH)2D3 binding were examined by incubating confluent cells overnight in media without or with 10(-6) M DEX. DEX decreased VDR number (B max) by approximately 70% (110 versus 32 fmol/mg cellular protein, p less than 0.001) without significantly changing the apparent affinity (K'D) of 1,25-(OH)2D3 for its receptor (3.8 versus 2.2 x 10(-10) M, p greater than 0.05). Overnight incubation of MG-63 cells with DEX produced a time- and dose-responsive decrease in VDR mRNA compared to untreated controls (p less than 0.01). To determine the mechanism of the DEX-mediated decrease in VDR mRNA, the effect of DEX on VDR mRNA stability was studied. We found that the half-life for the VDR mRNA was approximately 5.7 h and was not significantly changed when the cells were incubated with DEX (approximately 6.3 h). We conclude that DEX decreases both VDR number and mRNA in MG-63 osteosarcoma cells. Since the half-life of VDR mRNA was not significantly modified by dexamethasone, glucocorticoids appear to decrease VDR mRNA by inhibiting VDR gene transcription or by affecting the processing of VDR mRNA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312760     DOI: 10.1002/jbmr.5650070105

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  9 in total

1.  Duodenal calcium transporter mRNA expression in stressed male rats treated with diazepam, fluoxetine, reboxetine, or venlafaxine.

Authors:  Narattaphol Charoenphandhu; Jarinthorn Teerapornpuntakit; Sarawut Lapmanee; Nateetip Krishnamra; Jantarima Charoenphandhu
Journal:  Mol Cell Biochem       Date:  2012-07-06       Impact factor: 3.396

Review 2.  Bone involvement in exogenous hypercortisolism.

Authors:  L Sinigaglia; D Mazzocchi; M Varenna
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

Review 3.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

4.  Vitamin D endocrine system and osteoblasts.

Authors:  Marjolein van Driel; Johannes P T M van Leeuwen
Journal:  Bonekey Rep       Date:  2014-02-05

Review 5.  Corticosteroid-Induced osteoporosis: detection and management.

Authors:  J D Adachi; A Papaioannou
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 6.  [Osteoporosis in rheumatoid arthritis--significance of alfacalcidol in prevention and therapy].

Authors:  E Schacht
Journal:  Z Rheumatol       Date:  2000       Impact factor: 1.372

7.  Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study.

Authors:  M Luengo; F Pons; M J Martinez de Osaba; C Picado
Journal:  Thorax       Date:  1994-11       Impact factor: 9.139

Review 8.  Vitamin D and gene networks in human osteoblasts.

Authors:  Jeroen van de Peppel; Johannes P T M van Leeuwen
Journal:  Front Physiol       Date:  2014-04-09       Impact factor: 4.566

9.  The association between diet and glucocorticoid treatment in patients with SLE.

Authors:  Cecilia Lourdudoss; Ingiäld Hafström; Johan Frostegård; Ronald van Vollenhoven
Journal:  Lupus Sci Med       Date:  2016-01-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.